FTH Overview

Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.

Wall Street analysts forecast FTH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FTH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Faeth Therapeutics, Inc revenue for the last quarter amounts to -37.67M USD, increased 417.87

Faeth Therapeutics, Inc. EPS for the last quarter amounts to -10739000.00 USD, increased 51.38

Faeth Therapeutics, Inc (FTH) has 29 emplpoyees as of July 05 2026.

Today FTH has the market capitalization of 590.85M USD.